India’s own home-grown biotech company

Group-02
 Biocon: Overview
• Established in 1978.
• India’s leading Bio Technology Company.

• Expertise to develop innovative technologies

and product.
• Two subsidiaries:

• Exemplary performance in profits and ever-

increasing value of its scrips
 Products
Productsand
andservices
services
•• Products:
Products:
– Bio pharmaceuticals
– Bio pharmaceuticals
– Enzymes.
Enzymes
––Food additives
– Food additives
• Services:
• –Services:
Custom research.
––Clinical research.
Custom research
– Clinical research
Clinical trials and drug testing in India

• India emerges as a preferred destination for

outsourcing clinical trials
• Testing of new drugs on humans-heading towards
providing the greatest source of human guinea pigs for
the global drug industry
• Human beings from developing countries are being
used as guinea pigs and are paid a pittance for the
huge losses in health and life suffered by them
 Indian advantage
• Cost savings
• Governments are not careful to ensure that clinical
tests don’t lead to human suffering and death
• Medical infrastructure
• Huge patient pool and skilled workers
• Indian volunteers are treatment naïve

• Liberal guidelines (not like western countries)

• No law to safeguard the interest of volunteers
Unethical practices of Biocon
• Illegal clinical traits by Biocon
– Shantha biotech failed to obtain proper consent
from patients.
– Biocon tested genetically modified form of insulin
without the proper approval from DCGI or GEAC

• Environmental infractions
– Not environmentally responsible- first plant at
Bangalore still running without effluent treatment
plant.
• Biocon enhances trade operations in
Bangladesh
– Pollution norms are not strictly followed.
– Clinical trials easily conducted without any
objection

• Procedural lapses at Biocon

– Skipped some critical procedural steps and
doesn’t intimate the changes in SOP’s.
– Imported intermediate drug without license from
Auspure Biotech limited, china.
Thank you